Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Servicing And Remanufacturing: US FDA, Stakeholders Try To Draw Distinction

Executive Summary

US FDA’s device center in concert with third-party servicers and original equipment manufacturers are working toward consensus on how to differentiate medtech "servicing" from "remanufacturing" activities. Progress was made at a recent workshop in laying out ways that better training and more data sharing will help.

You may also be interested in...



Senators Want Answers From FDA Soon On Device Servicing Versus Remanufacturing

US Senators Elizabeth Warren and Bill Cassidy recently sent a letter to FDA acting commissioner Ned Sharpless prodding him to provide them details by 1 November on how the agency plans to regulate medical device servicers that may actually be remanufacturing devices.

New MITA Standard Helps Servicers Of Imaging Devices Develop Quality Systems, Avoid Remanufacturing

The Medical Imaging & Technology Alliance has released a voluntary standard that guides servicers of medical imaging equipment on how to best set up a quality system. NEMA/MITA 2 also aims to keep servicers from crossing the line into remanufacturing – an FDA-regulated activity.

Trade Group Suggests New Guidelines On Imaging Device Servicing, Remanufacturing

A new white paper from the Medical Imaging & Technology Alliance suggests ways US FDA could better distinguish between imaging device servicing and remanufacturing. The agency has previously announced plans to clarify the difference.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel